Relapse of hematologic malignancies after allogeneic stem cell transplantation remains a common problem, in particular for patients who have advanced disease at the time of transplantation. Thiotepa has excellent antileukemic and immunosuppressive activity, and could therefore be a useful drug in the conditioning regimen for patients with advanced hematologic neoplasms. We retrospectively analyzed toxicity, engraftment and survival data of 41 patients who received a conditioning regimen of thiotepa (600 mg/m 2 ) and hyperfractionated TBI (10 Gy) prior to matched related (n ¼ 25) or matched unrelated (n ¼ 16) allogeneic stem cell transplantation. The mean age at transplantation was 37.8 years (range 20-59), all but five patients had advanced hematologic malignancies at the time of transplantation. GVHD prophylaxis was with standard cyclosporine and methotrexate. Engraftment was excellent, but the regimen was associated with a high incidence of grade III renal (41%) and hepatic (15%) toxicity, and high transplant-related mortality (44% at day þ 90). The 3-year event-free survival was 13% and overall survival 14%. We conclude that this regimen requires modification to reduce toxicity. Bone Marrow Transplantation (2004) 34, 577-580. doi:10.1038/sj.bmt.1704642 Published online 2 August 2004 Keywords: thiotepa; TBI; transplantation Allogeneic hematopoietic stem cell transplantation (HSCT) is a successful therapeutic modality for a number of malignant and nonmalignant hematologic disorders. Although the importance of the graft-versus-malignancy effect is increasingly recognized, the success of allogeneic HSCT depends in part on the efficacy of the pretransplant conditioning regimen to eradicate residual malignant cells. This is of particular importance for patients with advanced disease (eg leukemia that is beyond CR1 or refractory to standard treatment). 'Standard' conditioning with cyclophosphamide and TBI relies primarily on irradiation to eradicate malignant cells, as cyclophosphamide is highly immunosuppressive but has only weak antileukemic activity. Dose escalation of TBI decreases the risk of relapse without improving overall survival (OS), due to an increase in transplant-related mortality (TRM).
Allogeneic hematopoietic stem cell transplantation (HSCT) is a successful therapeutic modality for a number of malignant and nonmalignant hematologic disorders. Although the importance of the graft-versus-malignancy effect is increasingly recognized, the success of allogeneic HSCT depends in part on the efficacy of the pretransplant conditioning regimen to eradicate residual malignant cells. This is of particular importance for patients with advanced disease (eg leukemia that is beyond CR1 or refractory to standard treatment). 'Standard' conditioning with cyclophosphamide and TBI relies primarily on irradiation to eradicate malignant cells, as cyclophosphamide is highly immunosuppressive but has only weak antileukemic activity. Dose escalation of TBI decreases the risk of relapse without improving overall survival (OS), due to an increase in transplant-related mortality (TRM). 1 A recent paper reported an inverse correlation between OS and TBI dose, with the best survival seen in patients receiving 10 Gy of total TBI. 2 Addition of other chemotherapeutic agents to the conditioning regimen generally results in the same increase in TRM as seen with increasing the radiation dose. 3 Thiotepa (N,N 0 ,N 00 -triethylenethiophosphoramide) is an alkylating agent used extensively in high-dose chemotherapy combinations for patients with breast cancer. 4 The usual dose of thiotepa in these treatment programs is 500-800 mg/m 2 , an eight-to 12-fold increase over standard dose levels. The two major organs affected by dose-limiting toxicities of thiotepa are the central nervous system (confusion, somnolence, coma) and the gastrointestinal tract (mucositis). 5 Thiotepa has a powerful antileukemic as well as a potent myeloablative effect. A combination of thiotepa (15 mg/kg) and cyclophosphamide (120 mg/kg) followed by allogeneic HSCT resulted in rapid engraftment and relatively low TRM in one study of adults with advanced leukemia. 6 In a population of children with high-risk neuroblastoma a combination of thiotepa (900 mg/m 2 ) and cyclophosphamide (6000 mg/m 2 ) with autologous stem cell rescue was well tolerated, and the progression-free survival compared favorably with TBI containing regimens. 7 Van Besien et al 8 recently reported their experience with a fludarabine-thiotepa (10 mg/kg)-TBI (12 Gy) conditioning regimen. Owing to a high incidence of delayed complications and a relatively high relapse rate, the regimen was ultimately abandoned. We report our single-institution experience with a conditioning regimen consisting of thiotepa (600 mg/m 2 ) and hyperfractionated TBI (10 Gy) prior to allogeneic HSCT for patients with advanced hematologic malignancies. Although the regimen resulted in excellent engraftment, it was associated with a high TRM.
Patients and methods

Patients
Data are reported on all consecutive patients treated with thiotepa and TBI conditioning followed by allogeneic HSCT. In total, 41 patients were treated between April 1994 and December 2002 for a variety of hematologic neoplasms. All patients were treated on an Institutional Review Board approved protocol and gave written informed consent prior to treatment. Eligibility criteria included pathologically confirmed diagnosis of hematologic malignancy, adequate pulmonary, cardiac, renal and liver function and absence of active infection. Four patients were transplanted with first chronic phase CML, and one patient was transplanted for AML in CR1; these patients were considered to have standard risk disease, all other patients had high-risk/advanced disease.
Conditioning
Conditioning consisted of thiotepa 300 mg/m 2 /day i.v. on days À4 and À3 (total dose 600 mg/m 2 ) and hyperfractionated TBI 200 cGy b.i.d. Â 5 doses on day À2, day À1 and day 0 (total dose 10 Gy). Non-T-cell depleted allogeneic bone marrow or peripheral blood stem cells were infused on day 0.
Supportive care
Patients were cared for in HEPA-filtered rooms throughout their admission. All patients received prophylactic acyclovir and antifungal prophylaxis (fluconazole or low-dose amphotericin-B) from admission until engraftment. GVHD prophylaxis consisted of cyclosporine A (or tacrolimus) from day À1 to day 180 at doses to maintain therapeutic trough levels and methotrexate 15 mg/m 2 i.v. on day þ 1 and 10 mg/m 2 i.v. on days þ 3, þ 6, and þ 11. All patients received PCP prophylaxis from engraftment until discontinuation of all immunosuppressive medication. Several patients received hematopoietic growth factors at various times after stem cell infusion as part of concurrent protocols. All patients received irradiated blood products, and CMV seronegative HSCT recipients received CMV negative blood products. Starting in June 2000 CMV antigenemia was monitored weekly and patients with evidence of CMV reactivation were treated with ganciclovir induction followed by ganciclovir maintenance until day þ 90. Patients received weekly i.v. immunoglobulin as needed to keep serum IgG levels above 400 mg/dl. Neutropenic fever was empirically treated with institution of broad-spectrum antibiotics (piperacillin plus gentamycin initially, in later years ceftazidime). Immunosuppressive medication was not interrupted for suspected or documented infection. Empiric antifungal coverage with amphotericin was started in case of fever persisting 472 h after the start of broad-spectrum antibiotic coverage with negative culture results. Acute GVHD was treated with methylprednisolone 2 mg/kg/day for a minimum of 7 days prior to taper in responsive patients. Several salvage regimens were used for patients with refractory acute GVHD.
Statistical methods
Engraftment was defined as the first of 3 consecutive days with ANCX0.5 Â 10 9 /l, and was confirmed by analysis of VNTR polymorphisms or by FISH analysis for XX/XY chromosomes. Acute GVHD was graded according to the Glucksberg criteria. 9 Toxicity was graded using the National Cancer Institute Toxicity Criteria. 10 The proportions of patients with a given characteristic were compared by the w 2 test. The duration of event-free survival (EFS) was calculated from the date of transplantation until the time of progression of disease, relapse, death, or the date the patient was last known to be in remission. The duration of OS was calculated from the date of transplantation until the time of death. Curves for EFS and OS were plotted according to the method of Kaplan and Meier and were compared by the log-rank test.
Results
Patients
Between April 1994 and November 2002 a total of 41 patients underwent an allogeneic HSCT, 25 with a matched sibling donor (MRD) and 16 with a matched unrelated donor (MUD) ( Table 1 ). The mean age at the time of transplant was 37.8 years (range 20-59 years); patients undergoing a MUD HSCT were significantly younger (mean age 29.2, range 20-49) than patient undergoing an MRD HSCT (mean age 41.8, range 21-59). All but five patients had advanced disease at the time of transplantation, with CML in first chronic phase and acute leukemia in CR1 considered standard/non-advanced disease. One patient underwent a T-cell depleted haplo-identical matched sibling transplant, all other procedures were with 5/6 or 6/6 HLA-matched T-cell replete grafts. Bone marrow was the source of stem cells for the majority (73%) of 
Engraftment, GVHD, and toxicity
Seven patients died prior to day þ 30, and were not evaluable for engraftment. All other patients engrafted, mean time to ANC 40.5 Â 10 9 /l was 20.7 days (range 12-32 days). Dose reduction and/or elimination of the fourth scheduled dose of methotrexate was necessary in 27 patients (65%), due to stomatitis. Engrafted patients were considered at risk for development of acute GVHD. Acute GVHD grade II-IV developed in 10/19 MRD recipients, and in 10/15 MUD recipients (Po0.05). A total of 23 patients were alive at day þ 90, and were considered evaluable for development of chronic GVHD. Chronic GVHD developed in 6/23 patients (no significant difference between MRD and MUD recipients), and was extensive in three and limited in three patients.
Early mortality was high, with a TRM at day þ 90 of 44% (MRD 56%, MUD 25%, Po0.05). Total nonrelapse mortality was 70%. Causes of treatment failure are summarized in Table 2 . Renal and hepatic toxicity were the most commonly encountered grade III organ toxicities, besides an expected high incidence of serious stomatitis (Table 3) . A distinct syndrome of hypotension, respiratory failure and renal failure was seen in 17 patients, within 30 days after transplantation. In the majority of these patients no infectious cause was identified, despite an extensive work-up (blood cultures, urine cultures, fiberoptic bronchoscopy with broncho-alveolar lavage), and these patients died with a picture of sepsis and multiorgan failure. Although viral cultures remained negative in these patients, no PCR for infectious viruses were performed during the study period, and occult viral infection can therefore not definitely be excluded as (contributing to) the cause of death.
Two out of 25 MRD patients relapsed (8%) at 68 and 96 days post transplant, two out of 16 MUD patients relapsed (12%) at 75 and 203 days post transplant. Eight patients are alive and without evidence of disease. Outcomes for patients with standard risk disease did not differ from patients with advanced disease (one out of five patients alive). With a median duration of follow-up of 38.4 months the estimated 3-year EFS is 17% for MRD patients and 9% for MUD patients (p NS), and the estimated 3-year OS is 17% for MRD patients and 11% for MUD patients (p NS) (Figure 1 ).
Discussion
Owing to its antileukemic and myelo-ablative properties, thiotepa has been incorporated into many conditioning regimens for HSCT. We retrospectively analyzed engraftment, toxicity, and survival after a conditioning regimen of high-dose thiotepa with 10 Gy TBI. As expected, the regimen resulted in a high engraftment rate. However, the very high TRM resulted in a poor EFS and OS. Multiorgan failure of a noninfectious etiology occurring within 30 days Table 2 Causes of treatment failure of HSCT contributed significantly to the high TRM encountered in our patient population. Many patients were transplanted after extensive exposure to previous chemotherapy regimens, and this undoubtly contributed to the high TRM. It is however interesting that serious toxicity of a thiotepa þ TBI combination has been reported by at least two other groups. Aversa et al 11 reported on the use of a conditioning regimen of TBI (8 Gy with lung shielding), thiotepa (10 mg/kg), fludarabine and ATG to perform Tcell-depleted haplo-identical allogeneic HSCT. Although no data on TRM is provided in their paper, they report a minimal nonhematologic toxicity, with a low incidence of severe mucositis. However, serious pulmonary toxicity occurred when they used higher lung doses of TBI with a higher dose of thiotepa (13 mg/kg), suggesting that the toxicity of a thiotepa/TBI combination increases abruptly above a critical threshold. In the recently published study from Van Besien et al 8 thiotepa (5 mg/kg/day for 2days) was combined with hyperfractionated TBI (2 Gy b.i.d. Â 6 doses, total dose 12 Gy). Early regimen-related toxicity was felt to be acceptable (4/30 deaths, 13%), but late pulmonary complications as well as a syndrome of thrombocytopenia and failure to thrive occurred frequently. As in our study, early toxicity consisted mainly of mucosal, pulmonary, renal, and hepatic toxicity. The 13 mg/kg dose reported to be associated with a high incidence of early toxicity comes closer to our dose of 600 mg/m 2 than the more commonly used dose of 10 mg/kg. A dose of 10 mg/kg was used by Zecca et al 12 in a study limited to children (median age 9 years) with ALL in CR1 or CR2 as part of a conditioning regimen consisting of TBI, thiotepa and cyclophosphamide. The lower median age in that series, the lower total dose of thiotepa, and the absence of methotrexate from the GVHD prophylaxis regimen probably explains the more favorable TRM of 15%.
MRD MUD
It is possible that the use of methotrexate for GVHD prophylaxis contributed to the high TRM. Methotrexate use is generally associated with more severe mucositis, and disruption of normal mucosal barriers is associated with an increased risk of bacteremia. 13 We used the same regimen of thiotepa and hyperfractionated TBI prior to autologous stem cell transplantation in 32 patients during the same time period. Characteristics of patients undergoing an autologous HSCT differed significantly from the allogeneic HSCT population, and a direct comparison is therefore not possible. It is however worth mentioning that the TRM among recipients of an autologous HSCT was only 12%. Studies by several groups have shown that the incidence of GVHD and TRM can be reduced significantly by incorporation of ATG or alemtuzumab in the conditioning regimen. 14 We conclude that this regimen in its present form is too toxic for use in patients with advanced hematologic malignancies and requires modification to reduce toxicity. To that extent we are presently studying a conditioning regimen combining a reduced dose of thiotepa with alemtuzumab and TBI.
